- Home
- LB vs EVO Comparison
LB vs EVO Comparison
Compare LB & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LB
- EVO
- Stock Information
- Founded
- LB 1992
- EVO 1993
- Country
- LB United States
- EVO Germany
- Employees
- LB N/A
- EVO N/A
- Industry
- LB
- EVO Biotechnology: Pharmaceutical Preparations
- Sector
- LB
- EVO Health Care
- Exchange
- LB NYSE
- EVO Nasdaq
- Market Cap
- LB 1.5B
- EVO 1.6B
- IPO Year
- LB 2024
- EVO 2021
- Fundamental
- Price
- LB $69.87
- EVO $4.09
- Analyst Decision
- LB Buy
- EVO Buy
- Analyst Count
- LB 8
- EVO 2
- Target Price
- LB $56.75
- EVO $5.90
- AVG Volume (30 Days)
- LB 618.0K
- EVO 92.6K
- Earning Date
- LB 05-07-2025
- EVO 04-17-2025
- Dividend Yield
- LB 0.29%
- EVO N/A
- EPS Growth
- LB N/A
- EVO N/A
- EPS
- LB 0.07
- EVO N/A
- Revenue
- LB $109,954,000.00
- EVO $825,103,013.00
- Revenue This Year
- LB $78.36
- EVO $12.17
- Revenue Next Year
- LB $16.81
- EVO $14.32
- P/E Ratio
- LB $969.63
- EVO N/A
- Revenue Growth
- LB 50.90
- EVO 1.99
- 52 Week Low
- LB $18.75
- EVO $2.84
- 52 Week High
- LB $84.70
- EVO $5.68
- Technical
- Relative Strength Index (RSI)
- LB N/A
- EVO 67.57
- Support Level
- LB N/A
- EVO $3.47
- Resistance Level
- LB N/A
- EVO $3.74
- Average True Range (ATR)
- LB 0.00
- EVO 0.15
- MACD
- LB 0.00
- EVO 0.13
- Stochastic Oscillator
- LB 0.00
- EVO 96.90
About LB LANDBRIDGE COMPANY LLC
LandBridge Co LLC is engaged in managing land and resources to support and promote oil and natural gas development. It generates revenue streams from the use of its surface acreage, the sale of resources from land and oil and gas royalties.
About EVO Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.